Over the past two decades, there has been remarkable progress in the management of haemophilia. Cloning of the genes encoding factor VIII and factor IX, together with advances in bioengineering have led to novel therapies that offer easier modes of administration, extended half-lives, and improved patient outcomes and quality of life. Managing haemophilia in children requires a multidisplinary approach, to provide comprehensive care and individualized treatment plans to meet the specific needs of the patients and their families.
